None listed
Conditions
Brief summary
The aim of this study is to investigate the different impact of slow versus fast injection of the anti-VEGF agent, ranibizumab, which is the treatment participants are receiving for the treatment of age-related macular degeneration (AMD). The study will run for 4 months and involve 2 study visits. Participants will receive the intravitreal injection that they are already receiving for AMD. The IOP will be measured before the injection, 2 minutes after the injection and 15 minutes after the injection. Study participants will be randomly assigned to two groups (group A and group B). Participants assigned to group A will receive their intravitreal injection as a quick push in the first visit and slowly (over 3-4 seconds) in the second visit. Participants assigned to group B will receive the opposite allocation. The two injections will be given 4-12 weeks apart according to the scheduled treatment for the participants AMD.
Interventions
Participants in this study will be patients who are receiving lucentis injections for the treatment of the Age-related Macular Degeneration. The trial will involve only measuring the intraocular pressure (IOP) before and after the injections to investigate the different impact of slow versus fast injections on IOP. The study will run for 4 months and involve 2 study visits. Participants will receive the intravitreal injection that they are already receiving for AMD. The IOP will be measured befo
Participants in this study will be patients who are receiving lucentis injections for the treatment of the Age-related Macular Degeneration. The trial will involve only measuring the intraocular pressure (IOP) before and after the injections to investigate the different impact of slow versus fast injections on IOP. The study will run for 4 months and involve 2 study visits. Participants will receive the intravitreal injection that they are already receiving for AMD. The IOP will be measured before the injection, 2 minutes after the injection and 15 minutes after the injection. Study participants will be randomly assigned to two groups (group A and group B). Participants assigned to group A will receive their intravitreal injection as a quick push in the first visit and slowly (over 3-4 seconds) in the second visit. Participants assigned to group B will receive the opposite allocation. The two injections will be given 4-12 weeks apart according to the scheduled treatment for the participants AMD."
Sponsors
The University of Sydney
Study design
Allocation
Randomised controlled trial
Primary purpose
Prevention
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age=or>50 years. 2. Clinical need for a therapeutic ranibizumab intravitreal injection for AMD. 3. A written informed consent is required before enrolling patients in the study.
Exclusion criteria
Patients with advanced glaucoma will be excluded from the study.
Outcome results
None listed